A phase 3 study of Regeneron Pharmaceuticals’ LAG-3 inhibitor failed to achieve its primary endpoint, marking the company’s second major late-stage setback within the past year.
The trial evaluated fianlimab in conjunction with Regeneron’s PD-1 inhibitor Libtayo as a first-line regimen for patients with unresectable locally developed or metastatic melanoma. The combination did not demonstrate a statistically significant progression-free survival (PFS) advantage over Merck & Co.’s PD-1 inhibitor Keytruda, resulting in the study missing its main goal.
Although median PFS was numerically higher with the fianlimab regimen (11.5 months at the higher dose compared with 6.4 months for Keytruda), the trial ultimately failed to meet statistical significance. Analysts at BMO Capital Markets explained in a note to investors, following discussions with Regeneron, that the result stemmed from delayed separation between the PFS curves during the study.
The analysts indicated that while the higher-dose fianlimab combination appeared to extend median PFS, the difference from monotherapy treatment emerged too late in the trial to produce a statistically meaningful result. They also noted there appeared to be an early indication of improved overall survival, which they viewed as slightly encouraging.
The p-value narrowly missed the threshold for statistical significance. However, BMO analysts emphasized that narrowly missing the mark did not alter the outcome. They described the failed study as a major disappointment for Regeneron, identifying it as one of the company’s most important expected catalysts for the first half of the year and suggesting the setback intensified pressure on the biotech.
That pressure began mounting nearly a year ago, when Regeneron and Sanofi disclosed that one of two phase 3 studies evaluating their IL-33 therapy itepekimab in chronic obstructive pulmonary disease had failed. According to BMO analysts, the consecutive setbacks involving key pipeline assets heightened the importance of Regeneron’s upcoming clinical development efforts over the next 12 to 18 months.
Regeneron still has potential opportunities to reposition fianlimab. A separate phase 3 trial comparing the high-dose fianlimab combination with Bristol Myers Squibb’s LAG-3/PD-1 immunotherapy Opdualag remains ongoing. Analysts at Evercore ISI suggested that demonstrating an overall survival benefit over Opdualag or meeting the study’s primary response rate endpoint could provide alternative paths forward for the therapy.
Despite those possibilities, both BMO and Evercore analysts removed fianlimab from their valuation models following the failed trial. BMO analysts acknowledged that Regeneron could still potentially demonstrate noninferiority against Opdualag, though they no longer viewed that scenario as the most likely outcome. Before excluding the drug from their forecasts, BMO and Evercore had projected risk-adjusted peak melanoma sales of $1.8 billion and $900 million, respectively.
With fianlimab now viewed as facing long odds, BMO analysts said positive clinical outcomes from Regeneron’s Factor XI program would likely become essential for rebuilding investor confidence. The company is currently advancing two Factor XI antibodies across a broader development strategy, with initial pivotal data anticipated in 2027 and additional readouts expected over the coming years.
Analysts also identified phase 3 results for the cemdisiran-pozelimab combination as another significant upcoming milestone. Data from pivotal studies evaluating the therapy in geographic atrophy and paroxysmal nocturnal hemoglobinuria are expected later this year.
Regeneron Faces Setback in Melanoma Research
Regeneron has encountered a significant hurdle after its melanoma drug failed to meet expectations in a late-stage Phase 3 clinical trial. The disappointing results have raised concerns among investors and healthcare analysts about the future of the treatment and its competitive position in the oncology market.
The recent trial evaluated the effectiveness of the Regeneron melanoma therapy in patients with advanced skin cancer. While earlier studies showed promising outcomes, the Phase 3 data revealed that the treatment did not achieve the desired improvement in survival rates compared to existing therapies.
Impact of the Regeneron Trial Results
The underperformance of the Regeneron drug may affect the company’s short-term oncology strategy. Experts believe the outcome could delay regulatory approvals and influence future partnerships in cancer research. Despite the setback, Regeneron remains one of the leading biotechnology companies investing heavily in innovative immunotherapy solutions.
Industry analysts note that melanoma treatment remains highly competitive, with several pharmaceutical companies introducing advanced therapies. The latest Regeneron results highlight the ongoing challenges of developing effective cancer drugs in late-stage clinical trials.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
